MedTrace Logo

Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites

NCT01956487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2017-06-12

No results posted yet for this study

Summary

Bioequivalence of propafenone hydrochloride capsules manufactured at two different sites

Conditions

  • Arrhythmia, Cardiac

Interventions

DRUG

Propafenone

Comparison of drug from 2 manufacturing sites

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-11
Primary Completion
2012-06-27
Completion
2012-06-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01956487 on ClinicalTrials.gov